Facebook
Twitter
LinkedIn
ForwardAcute Liver Failure: Science and Practice - Internet Activity (EM2212E)
Acute liver failure (ALF) is a rare but devastating condition that arises from diverse etiologies, has a high mortality and requires high resource utilization including transplantation. The Acute Liver Failure Study Group (ALFSG) has been funded by the National Institutes of Health (NIDDK) since 1997 to collect detailed clinical data on more than 3,500 ALF patients and closed its registry, database and bio-repository permanently in 2019.
This on-demand program, recorded at the 2-day live symposium, will provide a comprehensive review of all aspects of the pathogenesis and treatment of ALF including possible future therapies. Work pertaining to pathogenesis, epidemiology and patient evaluation, and further aspects of disease management (ICU management, treatment and consideration of prognosis, liver transplantation and liver support devices) will be reviewed.
The target audience includes basic scientists that work on liver injury as well as clinicians (hepatologists, surgeons) who care for these very ill patients.
This course/program is endorsed by AASLD. The Acute Liver Failure Study Group is pleased to have received the endorsement of the American Association for the Study of Liver Diseases (AASLD). Copyright © 2022 by the American Association for the Study of Liver Diseases. All rights reserved.
DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
METHOD OF PARTICIPATION
This continuing medical education enduring material is in a video format.
In order to receive AMA PRA Category 1 Credit(s)™ and ABIM MOC points, you should:
1. View the videos in this enduring material.
2. Complete the posttests (A passing score of 75% is required).
3. Complete and submit the CME evaluation form.
Eligible credit amounts are listed in each session.
Hardware/software requirements: Activities should be run with recent versions of common browsers, including Internet Explorer, Mozilla Firefox, and Google Chrome.
If you have questions about the participation process, please e-mail the UT Southwestern Medical Center, cmeregistrations@utsouthwestern.edu.
Target Audience
THIS ACTIVITY IS INTENDED FOR PROVIDERS AND RESEARCHERS IN THE SPECIALTIES OF:
- Gastroenterology and Hepatology
- Critical Care Medicine
- Surgery
- Anesthesiology
Learning Objectives
- Describe the differences between liver injury from acetaminophen (APAP) vs. other drugs.
- Restate the role of cytokines in relation to injury evolution
- Explain basic factors that promote liver regeneration.
- Discuss different mechanisms of liver injury and the role of genomics in susceptibility to acute liver failure.
- Describe the current state of genome wide association studies.
- Review current state of identification of single nucleotide polymorphisms (SNPs) for specific diseases/drug injuries
- Review the elements of the basic and advanced work-ups for ALF patients.
- Identify natural history, differences in presentation, and how etiology drives prognosis and transplant decisions.
- Describe the circulatory and neurological physiology of ALF.
- Explain new understanding regarding hemostasis in ALF, management of kidney injury and hemostasis
- Compare present treatment modalities and propose possible future management protocols.
- Contrast the differences in presentation and outcome of different etiologies.
- Relate how etiology drives prognosis and transplant decisions.
- Envision novel approaches to managing ALF in the future.
- Describe current issues surrounding liver support devices.
Acute Liver Failure: Science and Practice, a symposium.
Session 1: Acute Liver Failure: Overview and Mechanisms of Liver Injury
2.0 AMA PRA Category 1 Credit(s)™
2.0 points in the ABIM MOC Program
Moderators: Brendan McGuire, M.D. (UAB) and William M. Lee, M.D. (UTSW)
Presentation Title | Speaker |
Welcome to UTSW from the University President | Daniel Podolsky, M.D. |
Introduction to the Meeting | Brendan McGuire, M.D. |
Acute Liver Failure and the ALF Study Group:1997-2022 | William M. Lee, M.D. |
Molecular Mechanisms of Acute Liver Failure | Lily Dara, M.D. |
Clinical Phenotypes of Acute Liver Failure | K. Rajender Reddy, M.D. |
Histopathology of Acute Liver Failure | David E. Kleiner, M.D., Ph.D. |
Session 2: Liver Regeneration and Response to Injury
1.75 AMA PRA Category 1 Credit(s)™
1.75 points in the ABIM MOC Program
Moderators: Adrian Reuben, M.D. (MUSC) and David Kleiner, M.D. (NCI)
Presentation Title | Speaker |
Overview of Basic Regenerative Mechanisms | Sanjeev Gupta, M.D. |
The immunological basis of liver injury | Evangelos Triantafyllou, Ph.D. |
Mechanisms of Liver Regeneration After Drug Induced Liver Injury | Udayan Apte, Ph.D., DABT |
The Pathophysiology Brain Edema | Christopher Rose, Ph.D. |
Session 3: Genomics and Viral Discovery
1.0 AMA PRA Category 1 Credit(s)™
1.0 points in the ABIM MOC Program
Moderators: Jorge Rakela, M.D. (Mayo Clinic) and Tony Bass, M.D. (UCSF)
Presentation Title | Speaker |
Viral Discovery in Acute Liver Failure | Charles Chiu, M.D., Ph.D. |
Acute Liver Failure: Biomarkers | Jorge L. Rakela, M.D., MACP, FAASLD |
Session 4: Diagnosis, Evaluation and Prognosis of ALF
1.75 AMA PRA Category 1 Credit(s)™
1.75 points in the ABIM MOC Program
Moderators: Bob Fontana, M.D. (Michigan) and Dan Ganger, M.D. (Northwestern)
Presentation Title | Speaker |
The Natural History of Acute Liver Failure: i.e., Spontaneous or Transplant-Free Survival (TFS) | Adrian Reuben MBBS, FRCP, FACG, FAASLD |
Causality Process of the ALFSG | Daniel R. Ganger, M.D., FAST, FAASLD |
Prognostic Indices: Determining Outcomes | David Koch M.D., MSCR |
13C Methacetin Breath Test & other Prognostic Tools in ALF | Robert J. Fontana, M.D. |
Session 5: Complications of ALF: Riding Out the Storm
2.0 AMA PRA Category 1 Credit(s)™
2.0 points in the ABIM MOC Program
Moderators: Iris Liou, M.D. (Univ. of Washington) and Anne Larson, M.D. (Univ. of Washington)
Presentation Title | Speaker |
Critical Care Management of ALF | Constantine J. Karvellas, M.D., SM, FRCPC, FCCM |
Bleeding in Acute Liver Failure: Is there a role for coagulopathy? | R. Todd Stravitz, M.D. |
Acute Liver Failure: The Decision to List for Transplant | Shannan Tujios, M.D. |
Liver Transplant in Acute Liver Failure: SRTR/ALFSG | Constantine J. Karvellas, M,D, SM, FRCPC, FCCM |
Session 6: Liver Support, Transplantation and The Future
1.25 AMA PRA Category 1 Credit(s)™
1.25 points in the ABIM MOC Program
Moderators: Anne Larson, M.D. (Univ. of Washington) and William M. Lee, M.D. (UTSW)
Presentation Title | Speaker |
Liver Support Machines: Current Status | Scott L. Nyberg, M.D., Ph.D. |
Pediatric ALF: Current Status | James E Squires M.D., MS |
Acute Liver Failure: Is It Going Away? | Babak J. Orandi, MD, PhD, MSc, FACS, ABOM Diplomate |
Course Directors
William M. Lee, M.D.
Meredith Mosle Chair in Liver Disease in Honor of Dr. William M. Lee
Professor of Internal Medicine
UT Southwestern Medical Center
Brendan McGuire, M.D.
Medical Director of Liver Transplant
Professor
The University of Alabama at Birmingham
DISCLOSURE OF FINANCIAL RELATIONSHIPS
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), The University of Texas Southwestern Medical Center, Office of Continuing Medical Education (UTSW CME) requires that the content of CME activities and related materials provide balance, independence, objectivity, and scientific rigor. Planning must be free of the influence or control of any ineligible company, and promote improvements or quality in healthcare. In accordance with ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, all persons in the position to control the content of an education activity are required to disclose all financial relationships in any amount occurring within the past 24 months with any ineligible company producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. UT Southwestern also considers ineligible those companies producing, marketing, selling, re-selling, or distributing healthcare products in development for future use on patients, such as healthcare product research companies. All reported financial relationships with ineligible companies are reviewed for relevancy and then mitigated through a content review process prior to the activity (where applicable).
The following is a listing of all individuals that contributed to the educational content of this activity and any reported financial relationships within the last 24 months:
NAME | ROLE | RELATIONSHIP | COMPANY |
Nathan (Tony) M. Bass, MB, ChB, PhD, FACP, FAASLD | Moderator | Independent Contractor | GSK Marathon Roche Evidera |
Daniel R. Ganger, M.D. | Moderator, Speaker | Professional Services | Gilead Mallinkrodt |
David G Koch, M.D., MSCR | Speaker | Professional Services | Blue Sky Specialty Pharmacy |
Scott Nyberg, M.D., Ph.D. | Speaker | Inventor Inventor Inventor Board member Sponsored research | Ponte Biomedical Cytotheryx Miromatrix Ponte Biomedical Miromatrix |
William M. Lee, M.D. | Course Director, Moderator, Speaker | Grant or Contract Grant or Contract Grant or Contract Grant or Contract Grant or Contract Grant or Contract Grant or Contract Grant or Contract Independent Contractor Independent Contractor Independent Contractor Independent Contractor Independent Contractor | Merck Intercept Conatus Novo Nordisk IL Alexion Eiger Gilead Genentech Forma Pharmaceuticals Seattle Genetics Karuna Cortexyme |
K. Rajender Reddy, M.D. | Speaker | Grant or Contract Grant or Contract Grant or Contract Grant or Contract Grant or Contract Grant or Contract Grant or Contract Grant or Contract Grant or Contract Independent Contractor Independent Contractor Independent Contractor Independent Contractor Independent Contractor | Mallinckrodt Exact Sciences Gilead Merck Intercept BMS Grifols Sequana Biovie Mallinkrodt Novo Nordisk Spark Therapeutics Genfit Novartis |
Christopher F. Rose, Ph.D. | Speaker | Grant or Contract | Horizon Lupin Neuractas Morphocell Aza Technologies Mallinckrodt River Stone Axcella |
R. Todd Stravitz, M.D., FAASLD | Speaker | Grant or Contract | Instrumentation Laboratory |
The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Texas Southwestern Medical Center designates this enduring material activity for a maximum of 9.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Eligible credit amounts are listed in each session.
Available Credit
- 9.75 AMA
- 9.75 Attendance
Price
REGISTRATION
To register:
- Login to your existing account or create an account in EthosCE, online learning management system, by selecting the "create an account" link.
- Return to this course page and select the sessions you wish to enroll.
- Select the "Enroll" button. Registration will be completed.
- You may select the link embedded in the session title from the listing under the "Register" tab to proceed to the activity.
Required Hardware/software
Activities should be run with recent versions of common browsers, including Internet Explorer, Mozilla Firefox, and Google Chrome.
If you have questions about the participation process, please e-mail the UT Southwestern Medical Center, cmeregistrations@utsouthwestern.edu.